Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 140,400 shares, an increase of 134.4% from the February 13th total of 59,900 shares. Based on an average daily volume of 7,730,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.4% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on PSTV. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Plus Therapeutics in a report on Tuesday, November 26th. Ascendiant Capital Markets lowered their price target on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th.
Read Our Latest Stock Analysis on PSTV
Plus Therapeutics Stock Down 9.5 %
About Plus Therapeutics
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Read More
- Five stocks we like better than Plus Therapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Are Dividend Champions? How to Invest in the Champions
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Technology Stocks Explained: Here’s What to Know About Tech
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.